Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States

Abstract Background:. We analyzed the cost-effectiveness of treating incident chronic myeloid leukemia in chronic phase (CML-CP) with generic imatinib when it becomes available in United States in 2016.

Saved in:

Bibliographic Details
Main Authors:	Padula, William V. (Author) , Hehlmann, Rüdiger (Author) , Müller, Martin Christian (Author) , Saußele, Susanne (Author)
Format:	Article (Journal)
Language:	English
Published:	4 March 2016
In:	Journal of the National Cancer Institute Year: 2016, Volume: 108, Issue: 7
ISSN:	1460-2105
DOI:	10.1093/jnci/djw003
Online Access:	Verlag, Volltext: http://dx.doi.org/10.1093/jnci/djw003 Verlag, Volltext: https://academic.oup.com/jnci/article/108/7/djw003/2412626
Author Notes:	William V. Padula, Richard A. Larson, Stacie B. Dusetzina, Jane F. Apperley, Rudiger Hehlmann, Michele Baccarani, Ekkehard Eigendorff, Joelle Guilhot, Francois Guilhot, Rudiger Hehlmann, Francois-Xavier Mahon, Giovanni Martinelli, Jiri Mayer, Martin C. Müller, Dietger Niederwieser, Susanne Saussele, Charles A. Schiffer, Richard T. Silver, Bengt Simonsson, Rena M. Conti

Description
Summary:	Abstract Background:. We analyzed the cost-effectiveness of treating incident chronic myeloid leukemia in chronic phase (CML-CP) with generic imatinib when it becomes available in United States in 2016.
Item Description:	Gesehen am 01.02.2019
Physical Description:	Online Resource
ISSN:	1460-2105
DOI:	10.1093/jnci/djw003